Evidence map›Paper›PMID 36289678›Full record

ArticleBiomedicines2022

Endostatin in 3D Fibrin Hydrogel Scaffolds Promotes Chondrogenic Differentiation in Swine Neonatal Meniscal Cells.

Valentina Rafaela Herrera Millar, Barbara Canciani, Laura Mangiavini, Joel Fernando Soares Filipe, Lucia Aidos, Margherita Pallaoro, Giuseppe Maria Peretti, Paola Pocar, Silvia Clotilde Modina, Alessia Di Giancamillo

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Valentina Rafaela Herrera MillarDepartment of Biomedical Sciences for Health, University of Milan, Via Mangiagalli 31, 20133 Milan, Italy.ORCID 0000-0002-6855-9279
Barbara CancianiIRCCS Istituto Ortopedico Galeazzi, Via Riccardo Galeazzi, 4, 20161 Milano, Italy.
Laura MangiaviniDepartment of Biomedical Sciences for Health, University of Milan, Via Mangiagalli 31, 20133 Milan, Italy.
Joel Fernando Soares FilipeDepartment of Veterinary Medicine and Animal Sciences (DIVAS), University of Milan, Via dell'Università 6, 26900 Lodi, Italy.ORCID 0000-0001-8849-2051
Lucia AidosDepartment of Biomedical Sciences for Health, University of Milan, Via Mangiagalli 31, 20133 Milan, Italy.
Margherita PallaoroDepartment of Veterinary Medicine and Animal Sciences (DIVAS), University of Milan, Via dell'Università 6, 26900 Lodi, Italy.ORCID 0000-0002-8292-4543
Giuseppe Maria PerettiDepartment of Biomedical Sciences for Health, University of Milan, Via Mangiagalli 31, 20133 Milan, Italy.ORCID 0000-0001-9341-7187
Paola PocarDepartment of Veterinary Medicine and Animal Sciences (DIVAS), University of Milan, Via dell'Università 6, 26900 Lodi, Italy.
Silvia Clotilde ModinaDepartment of Veterinary Medicine and Animal Sciences (DIVAS), University of Milan, Via dell'Università 6, 26900 Lodi, Italy.ORCID 0000-0002-2780-5971
Alessia Di GiancamilloDepartment of Biomedical Sciences for Health, University of Milan, Via Mangiagalli 31, 20133 Milan, Italy.ORCID 0000-0003-1674-3020
University of Milan · ITIstituto Ortopedico Galeazzi · IT

Funding

Ministero della Salute L1036, L1044
6 · The paper itself

Abstract

The success of cell-based approaches for the treatment of cartilage or fibro-cartilaginous tissue defects requires an optimal cell source with chondrogenic differentiation ability that maintains its differentiated properties and stability following implantation. For this purpose, the aim of this study was to evaluate the use of endostatin (COL18A1), an anti-angiogenic factor, which is physiologically involved in cell differentiation during meniscus development. Swine neonatal meniscal cells not yet subjected to mechanical stimuli were extracted, cultured in fibrin hydrogel scaffolds, and treated at two different time points (T1 = 9 days and T2 = 21 days) with different concentrations of COL18A1 (10 ng/mL; 100 ng/mL; 200 ng/mL). At the end of the treatments, the scaffolds were examined through biochemical, molecular, and histochemical analyses. The results showed that the higher concentration of COL18A1 promotes a fibro-chondrogenic phenotype and improves cellularity index (DNA content, p < 0.001) and cell efficiency (GAGs/DNA ratio, p < 0.01) after 21 days. These data are supported by the molecular analysis of collagen type I (COL1A1, a marker of fibrous-like tissue, p < 0.001), collagen type II (COL2A1, a marker of cartilaginous-like tissue, p < 0.001) and SRY-Box Transcription Factor 9 (SOX9, an early marker of chondrogenicity, p < 0.001), as well as by histological analysis (Safranin-O staining), laying the foundations for future studies evaluating the involvement of 3D endostatin hydrogel scaffolds in the differentiation of avascular tissues.

Indexed as

chondrocytedifferentiationendostatinfibrin hydrogel scaffoldmeniscal tissue engineeringmorphology

Identifiers

PMID36289678
PMCPMC9598439
OpenAlexW4297348216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.